

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

**POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING
HELD ON JUNE 19, 2025;
THE REPURCHASE AND CANCELLATION OF ACQUIRED
AWARD SHARES AND THE REDUCTION OF
THE REGISTERED SHARE CAPITAL;
AND
AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The Board is pleased to announce that all the resolutions set out in the Notice of the AGM were duly passed by the Shareholders by way of poll at the AGM.

The 2024 annual general meeting (the “**AGM**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) was convened at 2:00 p.m. on Thursday, June 19, 2025 at Room 302, 3/F, Building 4, No. 590 Ruiqing Road, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, PRC. References are made to the notice (the “**Notice of the AGM**”) and the circular (the “**Circular**”) of the AGM of the Company both dated May 28, 2025. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The AGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and chaired by Mr. Philip Li Wang, the Chairman of the Board and an executive Director.

ATTENDANCE AT THE AGM

As of the date of the AGM, the total number of issued ordinary Shares was 243,937,000 Shares, comprising 236,223,322 H Shares and 7,713,678 Unlisted Foreign Shares. Pursuant to Rule 17.05A of the Listing Rules, the trustee of the 2022 H Share Incentive Scheme abstained from voting at the AGM in respect of the unvested incentive Shares (i.e. 519,900 H Shares) held by it. As a result, the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the AGM was 243,417,100 Shares.

Shareholders (including proxies) representing 130,563,451 Shares (including 122,849,773 H Shares and 7,713,678 Unlisted Foreign Shares) or approximately 53.52% of the total issued Shares of the Company attended the AGM.

Save as disclosed above, to the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

All Directors, namely Mr. Philip Li Wang, Mr. Yunqing Wang, Ms. Peili Wang, Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang, attended the AGM either in person or by electronic means.

POLL RESULTS OF THE AGM

The poll results of the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Votes (%) ^{Note}		
		For	Against	Abstain
1.	To consider and approve the work report of board of directors of the Company (the “ Board ”) for 2024.	130,563,451 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the work report of supervisory committee of the Company (the “ Supervisory Committee ”) for 2024.	130,563,451 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the profit distribution plan of the Company for 2024.	130,563,451 (100%)	0 (0%)	0 (0%)

Ordinary Resolutions		Number of Votes (%) ^{Note}		
		For	Against	Abstain
4.	To consider and approve the audited consolidated financial statements of the Company for 2024.	130,563,451 (100%)	0 (0%)	0 (0%)
5.	To consider and approve the annual report of the Company for 2024.	130,563,451 (100%)	0 (0%)	0 (0%)
6.	To consider and approve the re-appointment of Ernst & Young Hua Ming LLP as the domestic auditor of the Company and Ernst & Young as the international auditor of the Company for a term until the conclusion of the next annual general meeting of the Company and to authorize the Board to determine their respective remuneration.	130,563,451 (100%)	0 (0%)	0 (0%)
7.	To authorize the Board to determine the remunerations of directors of the Company.	130,563,451 (100%)	0 (0%)	0 (0%)
8.	To authorize the Supervisory Committee to determine the remunerations of the supervisors of the Company.	130,563,451 (100%)	0 (0%)	0 (0%)
Special Resolutions		Number of Votes (%) ^{Note}		
		For	Against	Abstain
9.	To consider and approve the proposal on the repurchase and cancellation of H Shares in relation to the 2022 H Share Incentive Scheme and the reduction of the registered share capital of the Company (the full text of the resolution is set out in the Notice of 2024 Annual General Meeting).	130,563,451 (100%)	0 (0%)	0 (0%)
10.	To consider and approve the proposed amendments to the articles of association of the Company.	130,563,451 (100%)	0 (0%)	0 (0%)
11.	To consider and approve issue additional H Shares, and additional Unlisted Foreign Shares (excluding treasury shares), in the share capital of the Company and to grant the Board a general mandate to issue additional shares (the full text of the resolution is set out in the Notice of 2024 Annual General Meeting).	119,207,061 (91.30%)	11,356,390 (8.70%)	0 (0%)

Note: All percentages are rounded to two decimal places.

As more than half of the votes were cast in favour of Ordinary Resolutions No. 1 to No. 8, and more than two-thirds of the votes were cast in favour of Special Resolutions No. 9 to No. 11, all resolutions proposed at the AGM were duly passed by way of poll by the Shareholders. The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The representatives of the Shareholders and the Supervisor participated in the scrutiny of the poll results.

REPURCHASE AND CANCELLATION OF ACQUIRED AWARD SHARES AND THE REDUCTION OF THE REGISTERED SHARE CAPITAL

References are made to the announcements of the Company dated May 23, 2025 and June 2, 2025 (the “**Announcements**”) and the Circular, in relation to (among other things) the proposal on the repurchase and cancellation of Acquired Award Shares and the reduction of the registered share capital of the Company (the “**Proposal**”) and the waiver granted by the Executive on May 30, 2025. The Proposal has been duly approved by Shareholders at the AGM by way of a special resolution. The repurchase and cancellation of Acquired Award Shares and the reduction of the registered share capital of the Company are subject to all the necessary approvals and filing procedures obtained therefor from the relevant competent authorities in the PRC. Further announcement(s) will be made by the Company in accordance with all applicable requirements of the Listing Rules as and when appropriate.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the Announcements and the Circular, in relation to (among other things) the proposed amendments to the Articles of Association. The proposal in relation to the amendments to the Articles of Association has been duly approved by Shareholders at the AGM by way of a special resolution. The relevant amendments to the Articles of Association will be made after completion of the Proposal and are subject to all the necessary approvals and filing procedures obtained therefor from the relevant competent authorities in the PRC. The full text of the amended Articles of Association will be published on the websites of the Stock Exchange and the Company after the amendments to Articles of Association have been made.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive Director

Shanghai, the People's Republic of China, June 19, 2025

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.